Hepatitis C Virus | Pharmacor | G7 | 2014

Last Updated 29 December 2014
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of it represents a large untapped market owing to high prevalence, a large pool of previously diagnosed, untreated, “warehoused” patients, and a substantial population of nonresponders who have not achieved sustained virologic response (SVR). The recent and imminent launches of multiple, very tolerable and effective, all-oral, interferon-free regimens will more than triple the number of drug-treated HCV patients in the major pharmaceutical markets under study and cause sales of HCV therapies to soar to nearly $30 billion during the forecast period.

Login to access report

launch Related Market Assessment Reports